Literature DB >> 8119686

Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis.

A S Petrides1, C Vogt, D Schulze-Berge, D Matthews, G Strohmeyer.   

Abstract

Glucose intolerance and diabetes mellitus are both prevalent in cirrhosis, yet the pathogenesis of impaired glucose metabolism remains unknown. Therefore insulin secretion (hyperglycemic clamp, +125 mg/dl), insulin sensitivity (euglycemic hyperinsulinemic insulin clamp, +10 microU/ml and +50 microU/ml), whole-body glucose oxidation (indirect calorimetry) and glucose turnover ([6,6-2H2]glucose isotope dilution) were evaluated in a homogenous group of cirrhotic patients with glucose intolerance (n = 7) or frank diabetes mellitus (n = 6). The results were compared with those obtained in control subjects (n = 8). In glucose-intolerant patients, whole-body glucose uptake (mainly reflecting glucose utilization by muscle) was significantly impaired in patients during both insulin infusions as a result of decreased stimulation of the two major intracellular pathways of glucose disposal--nonoxidative glucose disposal (i.e., glycogen synthesis) and glucose oxidation. Hepatic glucose production was normal in the basal state and was normally suppressed during stepwise insulin infusion (by 65% and 85%, respectively, p = NS vs. controls). Hyperglycemia-induced increases of plasma C-peptide concentrations were comparable to those in controls (p = NS). In diabetic patients, insulin-mediated glucose uptake was significantly reduced, mainly because of impaired non-oxidative glucose disposal. Glucose oxidation appeared to be reduced, too. Hepatic glucose production was significantly increased in the basal state (3.03 +/- 0.24 vs. 2.34 +/- 0.10 mg/kg min, p < 0.02) and during insulin infusion (+50 microU/ml: 0.67 +/- 0.17 vs. 0.13 +/- 0.08 mg/kg min, p < 0.05) compared with that in controls. Both the first and second phases of beta-cell secretion were significantly reduced in response to steady-state hyperglycemia (both p < 0.01 vs. control values). In conclusion, glucose intolerance in cirrhosis results from two abnormalities that occur simultaneously: (a) insulin resistance of muscle and (b) an inadequate response (even when comparable to that of controls) of the beta-cells to appropriately secrete insulin to overcome the defect in insulin action. Diabetes mellitus in insulin-resistant cirrhotic patients develops as the result of progressive impairment in insulin secretion together with the development of hepatic insulin resistance leading to fasting hyperglycemia and a diabetic glucose tolerance profile.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8119686     DOI: 10.1002/hep.1840190312

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  47 in total

1.  Community-acquired spontaneous Klebsiella pneumoniae meningitis in adult cirrhotic patients with and without diabetes.

Authors:  W N Chang; C H Lu; J J Wu; C B Lei; C R Huang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-22       Impact factor: 3.267

Review 2.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 3.  Interaction between hepatitis C virus and metabolic factors.

Authors:  Yasunori Kawaguchi; Toshihiko Mizuta
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  Long-Term Administration of Fibroblast Growth Factor 21 Prevents Chemically-Induced Hepatocarcinogenesis in Mice.

Authors:  Pengfei Xu; Yingjie Zhang; Wenfei Wang; Qingyan Yuan; Zhihang Liu; Lubna Muhi Rasoul; Qiang Wu; Mingyao Liu; Xianlong Ye; Deshan Li; Guiping Ren
Journal:  Dig Dis Sci       Date:  2015-05-24       Impact factor: 3.199

Review 5.  Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

6.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Authors:  E Bugianesi; A Gastaldelli; E Vanni; R Gambino; M Cassader; S Baldi; V Ponti; G Pagano; E Ferrannini; M Rizzetto
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

7.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.

Authors:  J A Davila; R O Morgan; Y Shaib; K A McGlynn; H B El-Serag
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

8.  Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.

Authors:  Ju Dong Yang; Hager Amed Mohamed; Jessica L Cvinar; Gregory J Gores; Lewis R Roberts; W Ray Kim
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

9.  Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.

Authors:  Donna L White; Vlad Ratziu; Hashem B El-Serag
Journal:  J Hepatol       Date:  2008-08-21       Impact factor: 25.083

Review 10.  Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.

Authors:  Diego Garcia-Compean; Joel Omar Jaquez-Quintana; Jose Alberto Gonzalez-Gonzalez; Hector Maldonado-Garza
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.